Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial

Lancet

Volumn 363, Issue 9426, 2004, Pages 2022-2031

  Julius, Stevo ^a,j   Kjeldsen, Sverre E ^a,b   Weber, Michael ^c   Brunner, Hans R ^d   Ekman, Steffan ^f   Hansson, Lennart ^e   Hua, Tsushung ^f   Laragh, John ^g   McInnes, Gordon T ^h   Mitchell, Lada ^f   Plat, Francis ^f   Schork, Anthony ^a   Smith, Beverly ^f   Zanchetti, Alberto ⁱ  

^a UNIVERSITY OF MICHIGAN   (United States)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c STATE UNIVERSITY OF NEW YORK   (United States)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e UPPSALA UNIVERSITY   (Sweden)

^f NOVARTIS PHARMA AG   (Switzerland)

^g WEILL CORNELL MEDICAL CENTER   (United States)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ UNIVERSITY OF MILAN   (Italy)

^j UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; VALSARTAN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; EDEMA; FEMALE; FOLLOW UP; HAZARD; HEADACHE; HUMAN; HYPERTENSION; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DIURETICS; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; RISK FACTORS; SODIUM CHLORIDE SYMPORTER INHIBITORS; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 2942635317     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16451-9     Document Type: Article

References (40)

1. Gong L, Zhang W, Zhu Y, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens. 14:1996;1237-1245
2. Staessen JA, Fagard T, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 350:1997;757-764
3. Liu L, Wang JG, Gong L, Liu G, Staessen JA, for the Systolic Hypertension in China (Syst-China) Collaborative Group. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens 1998; 16: 1823-29.
4. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 342:2000;145-153
5. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 353:1999;611-616
6. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 354:1999;1751-1756
7. Davis BR, Furberg CD, Wright JT, et al. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 283:2000;1967-1975
8. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and (-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) Study. Lancet. 356:2000;359-365
9. Brown M, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 356:2000;366-372
10. Furberg CD, Wright JT, Davis BR, et al. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 288:2002;2981-2997
11. Black H, Elliot W, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) trial. JAMA. 289:2003;2073-2082
12. Zanchetti A, Bond M, Hennig M, et al. Calcium-antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Circulation. 106:2002;2422-2427
13. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 290:2003;2805-2816
14. Staessen JA, Wang J-G, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 21:2003;1055-1076
15. Blood Pressure Lowering Treatment Trialists' Collaboration. Effect of different blood-pressure lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 362:2003;1527-1535
16. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 359:2002;995-1003
17. Wing L, Reid C, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 348:2003;583-592
18. Mann J, Julius S, for the VALUE Trial Group. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) Trial of Cardiovascular Events in Hypertension. Rationale and Design. Blood Press 1998; 7: 176-83.
19. Kjeldsen SE, Julius S, Brunner HR, et al. Characteristics of 15314 hypertensive patients at high coronary risk. The VALUE Trial. Blood Press. 10:2001;83-91
20. Julius S, Kjeldsen SE, Brunner HR, et al. for the VALUE Trial. VALUE Trial: Long-term BPtrends in 13, 449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003; 16: 544-48.
21. Brunner HR. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol. 87:2001;3C-9C
22. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease.Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 335:1990;827-839
23. WHO. Department of Non-Communicable Disease Surveillance. WHO criteria for diagnosis of diabetes mellitus. 1999;1-59 World Health Organization, 1999, Geneva
24. Okin PM, Roman MJ, Devereux RB, Kligfield P. J Am Coll Cardiol. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. 25:1995;417-423
25. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of left ventricular hypertrophy: test performance in relation to definition of hypertrophy and presence of obesity. J Am Coll Cardiol. 27:1996;124-131
26. Lithell H, Hansson L, Skoog I, et al. for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. J Hypertens 2003; 21: 875-86.
27. Collaborative Group. PROGRESS. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 358:2001;1033-1041
28. Investigators. EUROPA. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 362:2003;782-788
29. Pool JL, Glazer R, Chiang YT, Gatlin M. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J Hum Hypertens. 13:1999;275-281
30. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75.
31. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 349:2003;1893-1906
32. Malacco E, Mancia G, Rappelli A, Menotti A, Zuccaro MS, Coppini A; Shell Investigators. Treatment of isolated systolic hypertension: the SHELL study results. Blood Press 2003; 12: 160-67.
33. Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med. 340:1999;1321-1328
34. Messerli FH, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 279:1998;1903-1907
35. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 289:2003;2560-2572
36. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 21:2003;1011-1053
37. WHO, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 21:2003;1983-1992
38. Julius S, Jamerson K, Mejia A, Krause L, Schork N, Jones K. The association of borderline hypertension with target organ changes and higher coronary risk. Tecumseh Blood Pressure study. JAMA. 264:1990;354-358
39. Criscione L, Bradley W, Buhlmayer P, et al. Valsartan, preclinical and clinical profile of an antihypertensive angiotensin-II antagonst. Cardiovasc Drug Rev. 13:1995;230-250
40. Weber M, Julius S, Kjeldsen SE, et al. for the Value Trial Group. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet. Published online Jun 14, 2004. http://image.thelancet.com/extras/04let5020web.pdf